MyMetabolon Login
© 2021 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Microbiome
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
    • Publications
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
    • Publications
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Precision Medicine

N = 1: Leveraging clinical metabolomics to help identify, diagnose and inform personalized treatment of rare diseases

While most global metabolomics studies typically involve groups of many biological samples to identify novel pathway disturbances across a given cohort, our proprietary clinical metabolomics solution can help practitioners quickly identify rare diseases and known pathways of disease for individual patients through a comprehensive profile of all small-molecule entities in a single plasma sample.

See More Solutions

Clinical metabolomics can play a pivotal role in advancing the practice of precision medicine because there is almost always a physiological manifestation of disease that is reflected in the patient’s metabolites. While genomic sequencing may reveal disease risk, clinical metabolomics provides an in vivo snapshot of the patient’s health in the current state, which can reveal actionable information to advance clinical decision-making, including tracking an individual patient’s health status overtime to assess treatment response.

Metabolon’s proprietary clinical metabolomics approach, as described in “Precision of a Clinical Metabolomics Profiling Platform for Use in the Identification of Inborn Errors of Metabolism,” in The Journal of Applied Laboratory Medicine is a proven method for the screening of metabolic diseases through the analysis of a multi-pronged mass spectrometry platform.

This application of clinical metabolomics has proven exceptionally significant for Inborn Errors of Metabolism (IEM) and rare disease detection. Today there are more than 7,000 rare and undiagnosed diseases. Often the clinical manifestations of those diseases are vague, or the metabolic pathway that is disturbed is not immediately apparent. Applying global, or untargeted, analytical approaches, whereprior knowledge of the affected metabolic pathway is not required, provides advantages over targeted analytical approaches by casting a wide net to measure as many biomarkers as possible, invaluable in a clinical setting.

We believe clinical metabolomics has the potential to transform precision medicine and dramatically advance diagnosis and treatment of patients suffering from rare and undiagnosed diseases.

Study Design

Data Interpretation

Our Platform

Learn More

Related Resources

See All Resources
Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease

Repurposing eflornithine to treat a patient with a rare ODC1 gain-of-function variant disease

Five Translational Insights Key to a Successful First-in-Human (FIH) Study

Five Translational Insights Key to a Successful First-in-Human (FIH) Study

How United Therapeutics leverages metabolomics to get closer to the phenotype increasing confidence in clinical trial decisions

How United Therapeutics leverages metabolomics to get closer to the phenotype increasing confidence in clinical trial decisions

Load more

Enlighten your research,
accelerate your discovery.

Demo Our Data

Contact Us

Talk with an expert

Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.

    Get a Project Quote
    Send a Message
    Corporate Headquarters

    617 Davis Drive, Suite 100
    Morrisville, NC 27560

    Mailing Address:
    P.O. Box 110407
    Research Triangle Park, NC  27709

    +1 (919) 572-1711
    +1 (919) 572-1721
    International Headquarters

    Metabolon GmbH

    Zeppelinstraße 3
    85399 Hallbergmoos
    Germany

    +49 89 99017752

    Metabolomics

    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Quality Assurance
    • Setting the Standard: The 4Cs
    • Insights & Discoveries

    Solutions

    • Products & Services
    • By Research & Development Phase
    • By Therapeutic Area
    • By Sector

    Insights

    • Our Latest Insights
    • Blog
    • News & Events
    • Publications

    Resources

    • Resource Library
    • Client Stories
    • COVID-19

    Company

    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
    Metabolon - Logo - Enlightening Life

    Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

    © 2022 Metabolon, Inc. All rights reserved. Privacy & Terms

    in